IRADIMED CORPORATION (IRMD)
| Market Cap | 1.08B |
| Revenue (ttm) | 83.81M |
| Net Income (ttm) | 22.48M |
| Shares Out | 12.78M |
| EPS (ttm) | 1.75 |
| PE Ratio | 48.28 |
| Forward PE | 44.16 |
| Dividend | $0.80 (0.95%) |
| Ex-Dividend Date | Feb 23, 2026 |
| Volume | 183,886 |
| Open | 89.17 |
| Previous Close | 89.08 |
| Day's Range | 83.42 - 90.25 |
| 52-Week Range | 50.31 - 107.90 |
| Beta | 1.12 |
| Analysts | Strong Buy |
| Price Target | 116.00 (+37.29%) |
| Earnings Date | May 1, 2026 |
About IRMD
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device. It also provides non-magnetic IV poles, wireless remote dis... [Read more]
Financial Performance
In 2025, IRADIMED CORPORATION's revenue was $83.81 million, an increase of 14.43% compared to the previous year's $73.24 million. Earnings were $22.48 million, an increase of 16.88%.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for IRMD stock is "Strong Buy" and the 12-month stock price target is $116.0.
News
IRADIMED CORPORATION to Hold First Quarter 2026 Financial Results Conference Call on May 1, 2026
ORLANDO, Fla., April 27, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2026 first quarter financial results before the market opens on ...
IRADIMED CORPORATION to Participate at the 25th Annual Needham Virtual Healthcare Conference
ORLANDO, Fla., April 10, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) today announced that it will participate in the 25th Annual Needham Virtual Healthcare Conference.
IRADIMED CORPORATION to Participate at the 38th Annual Roth Conference
ORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) today announced that it will participate in the 38 th Annual Roth Conference.
IRADIMED CORPORATION Earnings Call Transcript: Q4 2025
Q4 2025 revenue rose 17% year-over-year to $22.7 million, with strong growth across all product lines and robust gross margins. The new 3870 pump launch is set to drive significant revenue growth in 2026, supported by positive early feedback and a large replacement market opportunity.
IRADIMED CORPORATION Reports Record Fourth Quarter and Full Year of 2025 Financial Results and Increases its Regular Quarterly Cash Dividend to $0.20 Per Share from $0.17 Per Share
ORLANDO, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company” or “Iradimed”) (NASDAQ: IRMD) announced today its financial results for the quarter and year ended December 31, 202...
IRADIMED Announces Special Cash Dividend of $0.50 Per Share
ORLANDO, Fla., Dec. 08, 2025 (GLOBE NEWSWIRE) -- iRadimed Corporation (the “Company”) (NASDAQ: IRMD), announced that its Board of Directors (the “Board”) approved a special cash dividend of $0.50 per ...
IRADIMED CORPORATION Named to TIME's List of America's Growth Leaders for 2026
Recognized for Exceptional Revenue Growth, Financial Stability, and Stock Performance Recognized for Exceptional Revenue Growth, Financial Stability, and Stock Performance
IRADIMED CORPORATION Earnings Call Transcript: Q3 2025
Q2 2025 delivered record revenue and earnings growth, driven by strong pump and monitor sales. FDA clearance of the new 3870 IV pump sets the stage for accelerated growth, with raised guidance and a $100M revenue run rate targeted for 2026.
IRADIMED CORPORATION Reports Record Third Quarter 2025 Financial Results
Announces Regular Quarterly Cash Dividend of $0.17 Per Share and Raises Full-Year Guidance Announces Regular Quarterly Cash Dividend of $0.17 Per Share and Raises Full-Year Guidance
IRADIMED CORPORATION to Hold Third Quarter of 2025 Financial Results Conference Call on November 3, 2025
ORLANDO, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 third quarter financial results before the market opens on M...
IRADIMED CORPORATION to Participate in the 2025 Wells Fargo Healthcare Conference
ORLANDO, Fla., Aug. 26, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), a leader in innovative medical devices for Magnetic Resonance Imaging (“MRI”) compatible patient monitoring and in...
IRADIMED CORPORATION Earnings Call Transcript: Q2 2025
Q2 2025 delivered record revenue and earnings growth, driven by strong pump and monitoring sales. FDA clearance of the 3870 pump sets up a major replacement cycle and higher ASPs, supporting raised 2025 guidance and a $100M+ run rate outlook for 2026.
IRADIMED CORPORATION Reports Record Second Quarter 2025 Financial Results
Announces Regular Quarterly Cash Dividend of $0.17 Per Share Raises Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $20.4 million for the second quarter of 2025, an increase of ...
IRADIMED CORPORATION to Hold Second Quarter of 2025 Financial Results Conference Call on August 1, 2025
ORLANDO, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 second quarter financial results before the market opens on ...
IRADIMED CORPORATION Announces FDA 510(k) Clearance for MRidium® 3870 Infusion Pump System
WINTER SPRINGS, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- Iradimed Corporation (NASDAQ: IRMD), a global leader in innovative medical devices for MRI environments, today announced that the U.S. Food and D...
IRADIMED CORPORATION Earnings Call Transcript: Q1 2025
Record Q1 2025 revenue rose 11% year-over-year, led by strong pump and disposable sales, with gross margin steady at 76.1%. Guidance for 2025 is reaffirmed, and the new facility and 3870 MRI IV pump are on track for key milestones.
IRADIMED CORPORATION Announces First Quarter 2025 Financial Results
Announces Regular Quarterly Cash Dividend of $0.17 Per Share Reaffirms Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $19.5 million for the first quarter of 2025, an increase o...
CORRECTION -- IRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025
WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by IRADIMED CORPORATION (NASDAQ: IRMD), please note that in the first paragraph the d...
IRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025
WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 first quarter financial results before the market op...
IRADIMED CORPORATION To Participate at the 37th Annual Roth Conference
WINTER SPRINGS, Fla., March 10, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced that it will participate in the 37 th Annual Roth Conference.
IRADIMED CORPORATION Earnings Call Transcript: Q4 2024
Record Q4 and full-year revenue growth driven by strong pump demand and domestic sales, with gross margin stable and robust backlog providing visibility into 2025. New product launches and facility expansion set the stage for further growth, while tariffs are expected to have minimal impact.
IRADIMED CORPORATION to Hold Fourth Quarter of 2024, Full Year of 2024 Financial Results Conference Call on February 13, 2025
WINTER SPRINGS, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2024 fourth quarter financial results before the market op...
IRADIMED CORPORATION Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025
Revenue reached $72 million in 2024, with strong growth expected as a new MRI-safe IV pump launches and a major replacement cycle begins. A new facility will support increased demand, and product innovation plus high barriers to entry position the business for multi-year expansion.
IRADIMED CORPORATION Reports Preliminary Unaudited Record Fourth Quarter and Full-Year 2024 Revenues
WINTER SPRINGS, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company” or “Iradimed”) (NASDAQ: IRMD), a leader in developing innovative Magnetic Resonance Imaging compatible medic...
IRADIMED CORPORATION to Present at the 43rd Annual J.P. Morgan Healthcare Conference
WINTER SPRINGS, Fla., Dec. 19, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (“MRI”) compatible medical devi...